Distribution Characteristics and Prognostic Value of Immune Infiltration in Oligometastatic Breast Cancer. 2021

Danyang Zhou, and Kuikui Jiang, and Ruoxi Hong, and Qianyi Lu, and Wen Xia, and Mei Li, and Chengyou Zheng, and Qiufan Zheng, and Fei Xu, and Shusen Wang
Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.

BACKGROUND To assess the distribution characteristics and the prognostic value of immune infiltration in female oligometastatic breast cancer patients. METHODS We retrospectively analyzed the clinicopathological data of oligometastatic breast cancer (OMBC) patients diagnosed between June 2000 and January 2020. Immune markers were quantified by immunohistochemistry on FFPE tissues in paired normal breast tissues, primary breast cancers and oligometastatic lesions. Survival analyses were performed using the Kaplan-Meier curves and Cox-proportional hazards model. RESULTS A total of 95 female OMBC patients visited Sun Yat-sen University Cancer Center between June 2000 and January 2020, and 33 of them had matched normal breast tissues, primary cancers and oligometastatic lesions and were reviewed in immune infiltration analysis. CD8 of primary tumors had a higher expression than that in matched normal tissues. The expressions of CD8 and FOXP3 were higher in the primary sites than that in the oligometastatic lesions. CD3, CD4 and CD8 were significantly lower in the intratumoral regions than that in the peritumoral regions both in primary and oligometastatic lesions. Notably, the high percentage of CD3 in the intratumoral oligometastatic lesions predicted the longer PFS and OS, and higher CD4 in the same lesions also predicted a better OS. There was obviously positive correlation between CD4/CD3 and Ki-67 in primary cancers and negative correlation between CD4/CD3 and ER in oligometastatic sites. CONCLUSIONS We explored immune distribution and evolution in time and space in OMBC to provide new understandings for biological behaviors of this disease and further divided patients in different prognosis.

UI MeSH Term Description Entries

Related Publications

Danyang Zhou, and Kuikui Jiang, and Ruoxi Hong, and Qianyi Lu, and Wen Xia, and Mei Li, and Chengyou Zheng, and Qiufan Zheng, and Fei Xu, and Shusen Wang
October 2025, Biomedicines,
Danyang Zhou, and Kuikui Jiang, and Ruoxi Hong, and Qianyi Lu, and Wen Xia, and Mei Li, and Chengyou Zheng, and Qiufan Zheng, and Fei Xu, and Shusen Wang
December 2023, Scientific reports,
Danyang Zhou, and Kuikui Jiang, and Ruoxi Hong, and Qianyi Lu, and Wen Xia, and Mei Li, and Chengyou Zheng, and Qiufan Zheng, and Fei Xu, and Shusen Wang
May 2013, Nan fang yi ke da xue xue bao = Journal of Southern Medical University,
Danyang Zhou, and Kuikui Jiang, and Ruoxi Hong, and Qianyi Lu, and Wen Xia, and Mei Li, and Chengyou Zheng, and Qiufan Zheng, and Fei Xu, and Shusen Wang
April 2013, Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae,
Danyang Zhou, and Kuikui Jiang, and Ruoxi Hong, and Qianyi Lu, and Wen Xia, and Mei Li, and Chengyou Zheng, and Qiufan Zheng, and Fei Xu, and Shusen Wang
June 2018, Zhonghua wai ke za zhi [Chinese journal of surgery],
Danyang Zhou, and Kuikui Jiang, and Ruoxi Hong, and Qianyi Lu, and Wen Xia, and Mei Li, and Chengyou Zheng, and Qiufan Zheng, and Fei Xu, and Shusen Wang
January 2021, Frontiers in genetics,
Danyang Zhou, and Kuikui Jiang, and Ruoxi Hong, and Qianyi Lu, and Wen Xia, and Mei Li, and Chengyou Zheng, and Qiufan Zheng, and Fei Xu, and Shusen Wang
January 2021, International journal of general medicine,
Danyang Zhou, and Kuikui Jiang, and Ruoxi Hong, and Qianyi Lu, and Wen Xia, and Mei Li, and Chengyou Zheng, and Qiufan Zheng, and Fei Xu, and Shusen Wang
December 2021, Cancer cell international,
Danyang Zhou, and Kuikui Jiang, and Ruoxi Hong, and Qianyi Lu, and Wen Xia, and Mei Li, and Chengyou Zheng, and Qiufan Zheng, and Fei Xu, and Shusen Wang
January 2024, Current cancer drug targets,
Danyang Zhou, and Kuikui Jiang, and Ruoxi Hong, and Qianyi Lu, and Wen Xia, and Mei Li, and Chengyou Zheng, and Qiufan Zheng, and Fei Xu, and Shusen Wang
February 2023, Breast (Edinburgh, Scotland),
Copied contents to your clipboard!